These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. Zafrir B; Egbaria A; Stein N; Elis A; Saliba W J Clin Lipidol; 2021; 15(1):202-211.e2. PubMed ID: 33243717 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762 [TBL] [Abstract][Full Text] [Related]
33. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360 [TBL] [Abstract][Full Text] [Related]
34. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937 [TBL] [Abstract][Full Text] [Related]
35. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation. Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795 [TBL] [Abstract][Full Text] [Related]
36. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686 [TBL] [Abstract][Full Text] [Related]
37. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye? Boffa MB; Koschinsky ML Curr Opin Lipidol; 2019 Dec; 30(6):428-437. PubMed ID: 31577611 [TBL] [Abstract][Full Text] [Related]
38. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861 [TBL] [Abstract][Full Text] [Related]
39. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526 [TBL] [Abstract][Full Text] [Related]
40. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity. Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]